Longevity.Technology notes that Daewoong Pharmaceutical has received a US patent nod for its mRNA-based cellular reprogramming technology.
Published
Signal category
Legal & Regulatory
Quote
“Daewoong Pharmaceutical has received a US patent nod for its mRNA-based cellular reprogramming technology, adding intellectual property support to its emerging anti-aging programme.”
— Longevity.Technology team
Company
Longevity.Technology
The #1 destination for daily news and insights on the fast-growth longevity market. LCW:the gateway to longevity clinics
- Industry
- Information Services
- Location
- London, GB
- Company size
- 18 employees
Just how close is technology that will enable humans to have hyper-extended lifespans? Closer than you think. Our mission is to bring together innovators, researchers, insurers, policy-makers, practitioners and commentators to address the new and fast-growing science and investment category that will shape the future of both the world’s population and the global economy: LONGEVITY
Founded 1997